F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma

F01 is a study for treating a type of blood cancer called non-Hodgkin's lymphoma. This cancer affects a part of your immune system called lymphocytes. Some people with this cancer might not get better with regular treatments. This study helps find out if F01 can help these people.

Key Points:

• 📅 The study will have two stages: dose escalation and dose expansion, testing different amounts of F01.
• 👥 You might be able to participate if you have a certain type of lymphoma and have already tried other treatments.
• ⚠️ Some risks include allergic reactions or other side effects. It's important to discuss these with your doctor.

Eligibility: You can join if you're at least 18, have been treated for lymphoma before, and have cancer that has come back or not responded to treatment. You should not have other serious health issues like certain heart or liver diseases.

Note: Talk to your doctor if you think you might want to participate in this study and to understand more about the treatment and potential risks.

💡 Always make sure to read and understand the informed consent form before joining any clinical study.